Systematic review of hepatocellular carcinoma mortality rates among hepatitis B virus- infected renal transplant recipients, with supplemental analyses of liver failure and all- cause mortality  Clarke Brian Blackadar  International Journal of Infectious Diseases  Volume 17, Issue 1, Pages e24-e36 (January 2013) DOI: 10.1016/j.ijid.2012.08.002 Copyright © 2012 International Society for Infectious Diseases Terms and Conditions

Figure 1 Flow diagram of the study selection process. (aUnusual follow-up (1), plagiarism (1), HBeAg-seropositive patients were treated with antivirals, leaving the healthier patients untreated (1), received correspondence that required the studies to be excluded (5); see results section for details.) International Journal of Infectious Diseases 2013 17, e24-e36DOI: (10.1016/j.ijid.2012.08.002) Copyright © 2012 International Society for Infectious Diseases Terms and Conditions

Figure 2 Mortality rates for HCC and 95% CI for HBsAg-seropositive renal transplant patients versus HBsAg-seropositive persons of the general population from Table 2. P-IV, Poisson inverse variance method. Dashed line centers on the overall rate, as calculated by the pooled method. International Journal of Infectious Diseases 2013 17, e24-e36DOI: (10.1016/j.ijid.2012.08.002) Copyright © 2012 International Society for Infectious Diseases Terms and Conditions

Figure 3 Mortality rates for NMLD and 95% CI for HBsAg-seropositive renal transplant patients and HBsAg-seropositive persons of the general population from Table 2. P-IV, Poisson inverse variance method. Dashed line centers on the overall rate, as calculated by the pooled method. International Journal of Infectious Diseases 2013 17, e24-e36DOI: (10.1016/j.ijid.2012.08.002) Copyright © 2012 International Society for Infectious Diseases Terms and Conditions

Figure 4 Relative rates (RR) of mortality due to all causes and 95% CI for HBsAg-seropositive renal transplant patients versus HBsAg-seronegative renal transplant patients from Table 4. International Journal of Infectious Diseases 2013 17, e24-e36DOI: (10.1016/j.ijid.2012.08.002) Copyright © 2012 International Society for Infectious Diseases Terms and Conditions

Figure 5 Meta-regression of the rate of all-cause mortality versus the dosage of steroids by random effects unrestricted maximum likelihood method. Slope=0.0010, df=17, I2=23.9%, p=0.0814. Dashed circles, HBsAg-seronegative renal transplant patients; solid circles, HBsAg-seropositive renal transplant patients. The circle size reflects the weight of the study for the meta-regression. International Journal of Infectious Diseases 2013 17, e24-e36DOI: (10.1016/j.ijid.2012.08.002) Copyright © 2012 International Society for Infectious Diseases Terms and Conditions